RUNX1 and acute myeloid leukemia: With RUNX1-RUNX1T1 expression, the expected block of differentiation has appeared on CD34 + human cord blood progenitor cells while coming into the differentiation state, with the fusion gene being degraded by CRISPR-Cas9 technology, which may provide novel insights into alternative treatment strategies for M2 AML [20, 23].